Hims & Hers Health, Inc. (NYSE:HIMS) Receives $20.71 Consensus Price Target from Brokerages

Hims & Hers Health, Inc. (NYSE:HIMS) has received a consensus rating of “Hold” from the sixteen analysts that are currently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, eight have given a hold recommendation and seven have issued a buy recommendation on the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $20.71.

HIMS has been the subject of a number of analyst reports. Bank of America lowered shares of Hims & Hers Health from a “buy” rating to an “underperform” rating and dropped their target price for the stock from $32.00 to $18.00 in a report on Thursday, November 14th. Needham & Company LLC started coverage on Hims & Hers Health in a research report on Thursday, August 22nd. They set a “buy” rating and a $24.00 price objective for the company. Piper Sandler reaffirmed a “neutral” rating and set a $21.00 target price (up previously from $18.00) on shares of Hims & Hers Health in a research note on Tuesday, November 5th. Imperial Capital downgraded Hims & Hers Health from an “outperform” rating to an “in-line” rating in a report on Friday, August 9th. Finally, Deutsche Bank Aktiengesellschaft raised their price target on shares of Hims & Hers Health from $23.00 to $27.00 and gave the company a “hold” rating in a research report on Wednesday, November 6th.

Insider Buying and Selling

In other Hims & Hers Health news, insider Soleil Boughton sold 2,345 shares of the firm’s stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $14.65, for a total transaction of $34,354.25. Following the sale, the insider now owns 159,796 shares in the company, valued at approximately $2,341,011.40. This trade represents a 1.45 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Patrick Harrison Carroll sold 15,000 shares of Hims & Hers Health stock in a transaction on Wednesday, November 6th. The shares were sold at an average price of $22.07, for a total transaction of $331,050.00. Following the transaction, the insider now owns 196,941 shares in the company, valued at approximately $4,346,487.87. This trade represents a 7.08 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 1,049,183 shares of company stock valued at $21,395,632. 17.71% of the stock is owned by insiders.

Institutional Investors Weigh In On Hims & Hers Health

Institutional investors and hedge funds have recently modified their holdings of the stock. Renaissance Technologies LLC grew its position in shares of Hims & Hers Health by 113.1% during the second quarter. Renaissance Technologies LLC now owns 6,039,408 shares of the company’s stock valued at $121,936,000 after purchasing an additional 3,205,108 shares in the last quarter. Farallon Capital Management LLC increased its position in shares of Hims & Hers Health by 3,890.5% during the 1st quarter. Farallon Capital Management LLC now owns 1,676,000 shares of the company’s stock valued at $25,928,000 after purchasing an additional 1,634,000 shares during the last quarter. Wellington Management Group LLP increased its position in Hims & Hers Health by 34.5% during the third quarter. Wellington Management Group LLP now owns 3,444,414 shares of the company’s stock valued at $63,446,000 after acquiring an additional 883,230 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of Hims & Hers Health by 12.7% during the 3rd quarter. Geode Capital Management LLC now owns 4,289,549 shares of the company’s stock worth $79,029,000 after purchasing an additional 482,177 shares during the period. Finally, Healthcare of Ontario Pension Plan Trust Fund boosted its position in shares of Hims & Hers Health by 164.1% during the second quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 528,142 shares of the company’s stock valued at $10,663,000 after buying an additional 328,142 shares during the period. Institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Stock Performance

Shares of HIMS stock opened at $31.39 on Thursday. The company has a market capitalization of $6.86 billion, a P/E ratio of 71.34 and a beta of 1.06. Hims & Hers Health has a fifty-two week low of $8.09 and a fifty-two week high of $31.40. The stock has a 50 day moving average price of $20.85 and a two-hundred day moving average price of $19.44.

Hims & Hers Health (NYSE:HIMS) last issued its earnings results on Monday, November 4th. The company reported $0.32 EPS for the quarter, topping the consensus estimate of $0.06 by $0.26. The company had revenue of $401.56 million for the quarter, compared to the consensus estimate of $382.20 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The firm’s revenue for the quarter was up 77.1% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.04) earnings per share. As a group, equities analysts predict that Hims & Hers Health will post 0.29 earnings per share for the current year.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.